Copper(II) complexes have great potential as antitumor and antimicrobial agents, and their coumarin derivatives bearing histamine substituents possess versatile structural and biological properties. The present article describes the synthesis of novel copper(II)–coumarin–histamine complexes and ligands and their characterization by IR, NMR, X-ray diffraction, and elemental analysis. Their antimicrobial activity (MIC, MBC/MFC) was tested against 11 reference strains. Cytotoxicity was evaluated using the MTT assay against 15 selected cancer cell lines and normal HMEC-1 cells. It presents three new ligands and three new complexes with copper(II) ions and selected histamine-containing coumarin derivatives. The new copper(II) complexes demonstrated markedly higher anticancer activity than their corresponding ligands across all evaluated cancer cell lines. The highest anticancer activity against the Hep3B liver cancer cell line was demonstrated by the copper(II) complex (3b), which also showed the strongest inhibition of S. epidermidis ATCC 12228 and S. aureus ATCC 6538. The copper(II) ions play a crucial role in the antitumor activity of these derivatives. Despite limited antimicrobial effects, the tested complexes, particularly 3a and 3b, demonstrate promising anticancer potential, especially against the Hep3B cancer cell line. Only 3b demonstrated antimicrobial activity against S. epidermidis ATCC 12228 and S. aureus ATCC 6538.
In this study, we show that cyclodextrin cavity size and guest molecule chemistry strongly affect crystal packing, intermolecular interactions, and stabilization mechanisms of the investigated inclusion complexes.
Chromone is an important structural motif in numerous biologically active natural and synthetic compounds. The aim of the present study is to synthesize and characterize a series of novel chromone derivatives bearing imidazole and pyrazole moieties. The synthesis involved a two-step procedure in which methyl 3-chromonecarboxylate derivatives were prepared and then condensed with imidazole and pyrazole analogues. The structures of the compounds were characterized using spectroscopy, single-crystal X-ray diffraction and Hirshfeld surface analysis. Compounds 1 and 1A were subjected to ITC titration in DMSO. Anticancer potential of synthetized substances was evaluated against three breast cancer cell lines (MCF-7, MDA-MB-231 and HCC38), and two endometrial cancer cell lines (Ishikawa and Hec-1-A). Compounds 1B and 1C, bearing 3-(1H-imidazol-1-yl)propan-1-amine and3-(3,5-dimethyl-4H-pyrazol-4-yl)propan-1-amine moieties, respectively, exhibited the most pronounced, albeit modest, cytotoxic activity against MCF-7 cells, with IC50 values of approximately 80 μM. In HMEC-1 human microvascular endothelial cells (used as a non-cancerous reference model), the same compounds lowered the signal of the dihydroethidium (DHE) probe, suggesting a modest antioxidant effect; these redox results are reported separately from the anticancer assays. The compounds were subjected to further complex analysis using 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA) and molecular docking studies. This complex approach provided a qualitative insight into the structure–activity relationships of the studied derivatives. Given the modest cytotoxicity and limited selectivity of Compounds 1B and 1C, together with their redox-modulating effect observed in HMEC-1 cells, these compounds should be regarded as a starting point for further investigation rather than as promising anticancer candidates.